Maravai Lifesciences Holdings (MRVI) Stock News

Maravai LifeSciences (NASDAQ: MRVI) has appointed Rajesh "Raj" Asarpota as Executive Vice President and Chief Financial Officer, effective June 30, 2025. He succeeds Kevin Herde, who will transition to an advisory role to support the transition.

Asarpota brings nearly three decades of executive leadership experience, including over 10 years as CFO in life sciences and medical device companies. He will lead Maravai's global Finance, Accounting, Treasury, Investor Relations, Corporate Strategy, and Information Technology teams, focusing on driving growth and profitability in nucleic acid technologies and bioprocess impurity analytics.

This CFO transition follows the recent appointment of Bernd Brust as CEO. The company will review its full-year 2025 financial guidance during its second-quarter earnings call in August.

Maravai LifeSciences (NASDAQ: MRVI) has appointed Bernd Brust as its new Chief Executive Officer and Board member, replacing William "Trey" Martin III, effective immediately. Brust brings over 30 years of leadership experience in life sciences, with expertise in transforming businesses into profitable ventures. The leadership change reflects Maravai's focus on accelerating innovation, execution, and financial performance. Brust's customer-centric approach aligns with Maravai's mission to advance scientific discovery in biologics and genomic medicine markets. The company maintains its position in mRNA and bioprocess impurity detection, with plans to enhance manufacturing capabilities. Maravai will review its 2025 financial guidance during the Q2 earnings call in August after Brust conducts a comprehensive business assessment.

TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has entered into a non-exclusive License and Supply Agreement with Quantoom Biosciences for CleanCap mRNA capping technology. The agreement allows Quantoom to integrate TriLink's CleanCap technology into its Ntensify (sa)mRNA production platform. CleanCap technology achieves over 95% efficiency in producing 5′ cap structures and significantly improves mRNA yield and process time compared to traditional methods. The partnership aims to accelerate RNA production and increase accessibility of therapeutics and vaccines globally. CleanCap technology, launched in 2017, is currently used in most approved COVID-19 mRNA and saRNA vaccines. The collaboration focuses on enabling Quantoom's customers to develop (sa)mRNA drugs through clinical development phases using the integrated platform.

Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.

The company demonstrated strong employee engagement with a 95% participation rate in their annual survey and expanded their employee resource programs. In governance, they appointed R. Andrew Eckert as independent Chairman and strengthened their intellectual property position. Sustainability initiatives included enhanced greenhouse gas emissions reporting and renewable energy projects, with their Leland facility's solar panels generating over 180,000 kWh.

Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.

The report details strong employee engagement with a 95% survey participation rate and expanded employee resource initiatives. In governance, the company appointed R. Andrew Eckert as independent Chairman and strengthened its intellectual property position. Sustainability efforts included enhanced greenhouse gas emissions reporting, solar energy generation at the Leland facility, and EV charging stations that saved over 19,000 gallons of gasoline.

TriLink BioTechnologies (NASDAQ: MRVI) has launched its first mRNA synthesis kit featuring CleanCap® capping technology. The all-in-one in vitro transcription (IVT) kit delivers up to 2X more mRNA yield and up to 85% lower dsRNA compared to market alternatives. The kit includes CleanCap® AG (3′ OMe), CleanScribe™ RNA Polymerase, nucleotides with N1-methylpseuouridine, and CleanScript® IVT.

To celebrate the launch, TriLink is donating ten kits each to seven academic institutions across the U.S. and Europe, including Houston Methodist Research Institute, UC San Diego, University Medical Center Utrecht, University of Oxford, and Yale School of Medicine. The donated kits can yield up to a combined 250mg of capped mRNAs.

The kit features CleanCap AG (3′ OMe) with over 95% capping efficiency for improved protein expression, streamlining mRNA manufacturing with fewer steps compared to traditional ARCA or enzymatic methods.

TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has signed a Memorandum of Understanding (MOU) with the International Vaccine Institute (IVI) to advance mRNA-based vaccine development. The collaboration aims to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives, with a focus on improving access in low- and middle-income countries (LMICs).

TriLink's CleanCap® technology, launched in 2017, is currently used in most approved COVID-19 mRNA and saRNA vaccines. In 2024, the company expanded its offerings with IVT enzymes and opened a GMP manufacturing facility in San Diego. IVI, established in 1997 in Seoul, focuses on developing vaccines for diseases affecting LMICs, including cholera, typhoid, chikungunya, and COVID-19.

Maravai LifeSciences (NASDAQ: MRVI) reported challenging Q1 2025 financial results with revenue of $46.9 million, down 27.0% year-over-year. The company posted a net loss of $(52.9) million, including a $12.4 million goodwill impairment, and negative Adjusted EBITDA of $(10.5) million. The decline was primarily driven by the Nucleic Acid Production segment, which fell 37.5% to $28.8 million due to lack of high-volume CleanCap orders for commercial vaccine programs. Biologics Safety Testing revenue remained relatively flat at $18.1 million. Despite challenges, management maintained full-year 2025 revenue guidance of $185.0-205.0 million, citing solid execution in their base business which grew by $4 million compared to Q4 2024.

Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT/ 5:00 p.m. ET on the same day.

Participants can join the conference call by dialing (800) 343-4849 or (203) 518-9848 and referencing Conference ID MARAVAI. The event will also be accessible via webcast through the "Investors" section of Maravai's website.